BioCentury | Feb 7, 2011
Clinical News

AS1411: Phase IIb discontinued

...aptamer in cancer indications other than AML. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
...aptamer in cancer indications other than AML. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Mar 29, 2010
Clinical News

AS1411: Phase IIb started

...or without 40 or 80 mg/kg/day AS1411. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Dec 21, 2009
Clinical News

AS1411: Interim Phase II data

...of AS1411 in AML in early 2010. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Dec 17, 2009
Clinical News

Antisoma discontinues AS1411 for RCC

...was up 0.50p to 35.50p on Wednesday. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Oct 19, 2009
Clinical News

AS1411 regulatory update

...it is also in Phase II testing. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Jun 8, 2009
Clinical News

AS1411: Additional Phase II data

...Society of Clinical Oncology meeting in Orlando. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Dec 22, 2008
Clinical News

AS1411: Interim Phase II data

...16 evaluable patients (see BioCentury, July 14). Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Apr 14, 2008
Product Development

Antisoma's MOA support

...lung cancer (NSCLC) last week (see B17). Antisoma gained AS1411 in its 2005 acquisition of Aptamera Inc....
BioCentury | Apr 14, 2008
Clinical News

Antisoma, Archemix preclinical data

...II testing for acute myeloid leukemia (AML). Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Oct 9, 2006
Clinical News

AS1411: Additional Phase I data

...AS1411 has Orphan Drug designation for pancreatic cancer. ASM gained AS1411 through its acquisition of Aptamera Inc....
Items per page:
1 - 10 of 25
BioCentury | Feb 7, 2011
Clinical News

AS1411: Phase IIb discontinued

...aptamer in cancer indications other than AML. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
...aptamer in cancer indications other than AML. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Mar 29, 2010
Clinical News

AS1411: Phase IIb started

...or without 40 or 80 mg/kg/day AS1411. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Dec 21, 2009
Clinical News

AS1411: Interim Phase II data

...of AS1411 in AML in early 2010. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Dec 17, 2009
Clinical News

Antisoma discontinues AS1411 for RCC

...was up 0.50p to 35.50p on Wednesday. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Oct 19, 2009
Clinical News

AS1411 regulatory update

...it is also in Phase II testing. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Jun 8, 2009
Clinical News

AS1411: Additional Phase II data

...Society of Clinical Oncology meeting in Orlando. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Dec 22, 2008
Clinical News

AS1411: Interim Phase II data

...16 evaluable patients (see BioCentury, July 14). Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Apr 14, 2008
Product Development

Antisoma's MOA support

...lung cancer (NSCLC) last week (see B17). Antisoma gained AS1411 in its 2005 acquisition of Aptamera Inc....
BioCentury | Apr 14, 2008
Clinical News

Antisoma, Archemix preclinical data

...II testing for acute myeloid leukemia (AML). Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
BioCentury | Oct 9, 2006
Clinical News

AS1411: Additional Phase I data

...AS1411 has Orphan Drug designation for pancreatic cancer. ASM gained AS1411 through its acquisition of Aptamera Inc....
Items per page:
1 - 10 of 25